Smith, Salley & Associates Illumina, Inc. Transaction History

Smith, Salley & Associates

$1.48 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$193.75 - $232.55 $9,493 - $11,394	-49 Reduced 4.08%	1,153 $268,000
Q1 2022 May 10, 2022	SELL	$303.87 - $423.8 $4,558 - $6,357	-15 Reduced 1.23%	1,202 $420,000
Q4 2021 Feb 10, 2022	SELL	$347.28 - $421.83 $1,041 - $1,265	-3 Reduced 0.25%	1,217 $463,000
Q2 2021 Aug 09, 2021	BUY	$372.84 - $481.5 $6,711 - $8,667	18 Added 1.5%	1,220 $578,000
Q1 2021 Apr 30, 2021	SELL	$361.28 - $504.76 $151,015 - $210,989	-418 Reduced 25.8%	1,202 $462,000
Q4 2020 Jan 28, 2021	BUY	$292.7 - $370.96 $292 - $370	1 Added 0.06%	1,620 $599,000
Q2 2020 Aug 04, 2020	SELL	$256.46 - $373.01 $769 - $1,119	-3 Reduced 0.18%	1,619 $600,000
Q1 2020 Apr 24, 2020	BUY	$209.2 - $335.53 $209 - $335	1 Added 0.06%	1,622 $443,000
Q3 2019 Oct 30, 2019	SELL	$266.84 - $378.23 $2,134 - $3,025	-8 Reduced 0.49%	1,621 $494,000
Q2 2019 Jul 12, 2019	BUY	$300.59 - $368.15 $300 - $368	1 Added 0.06%	1,629 $599,000
Q1 2019 May 03, 2019	SELL	$272.57 - $321.18 $1,635 - $1,927	-6 Reduced 0.37%	1,628 $506,000
Q4 2018 Feb 05, 2019	SELL	$272.46 - $366.54 $5,449 - $7,330	-20 Reduced 1.21%	1,634 $490,000
Q3 2018 Nov 06, 2018	BUY	$279.04 - $367.06 $1,674 - $2,202	6 Added 0.36%	1,654 $607,000
Q2 2018 Aug 10, 2018	BUY	$228.17 - $292.07 $1,140 - $1,460	5 Added 0.3%	1,648 $460,000
Q1 2018 May 09, 2018	SELL	$209.54 - $253.91 $32,688 - $39,609	-156 Reduced 8.67%	1,643 $388,000
Q4 2017 Feb 12, 2018	SELL	$202.23 - $230.03 $31,345 - $35,654	-155 Reduced 7.93%	1,799 $393,000
Q3 2017 Nov 02, 2017	BUY	$172.3 - $213.93 $336,674 - $418,019	1,954	1,954 $389,000

Others Institutions Holding ILMN

# of Institutions

901

Shares Held

137M

Call Options Held

1.22M

Put Options Held

1.43M

View Full List

About ILLUMINA, INC.

Ticker ILMN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 157,300,000
Market Cap $22.7B
Description
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments....

More about ILMN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Salley & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Smith, Salley & Associates with notifications on news.

Account